Polen Capital Management, LLC, an independently-owned global investment manager, recently published its first-quarter focus growth commentary – a copy of which can be downloaded...
Keep Reading →
April 28 - Hedge Fund Investor Letters
Hedge fund manager Ali Lumsden gained 73% the last time the mortgage-bond market went into meltdown. This time around, the veteran investor is on the wrong side of the crisis.
Keep Reading →
April 21 - Hedge Funds, Insider Trading
For Jim Simons, history is repeating itself, at least when it comes to meltdowns in the quant fund world.
Keep Reading →
April 17 - Hedge Funds, Insider Trading
Coronavirus is probably the #1 concern in investors' minds right now. It should be.
Keep Reading →
March 12 - Hedge Funds, News
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.
Keep Reading →
December 26 - Hedge Funds, News
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Keep Reading →
December 4 - Hedge Funds, News
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Keep Reading →
October 10 - Hedge Funds, News
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in...
Keep Reading →
June 14 - Hedge Funds, News
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions...
Keep Reading →
March 28 - Hedge Funds, News
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Keep Reading →
December 11 - Hedge Funds, News
Florida-based investment manager Polen Capital is bullish on Regeneron Pharmaceuticals Inc (NASDAQ:REGN), a New York-based biotech company with six FDA-approved medicines and ...
Keep Reading →
January 30 - News
Correction: A previous version of this article erroneously presented older events about the case between Sanofi/Regeneron and Amgen.
Keep Reading →
February 9 - News, Stock Analysis
Have you ever wondered which are the highest paid CEOs in the world? Companies in the corporate world are ready to push to the limits to compensate their CEOs, despite of the ...
Keep Reading →
January 30 - Lists, News
Thursday was a big day for two companies, in two very different ways, in the biotech space.
Keep Reading →
December 9 - News, Stock Analysis
The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (...
Keep Reading →
December 9 - News, Stock Analysis
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns.
Keep Reading →
December 7 - Hedge Funds, News
Eylea has been one of the main drivers of growth for Regeneron over the past couple of years.
Keep Reading →
November 8 - News, Stock Analysis
It's another quiet day on the Street as the main indexes are moderately in the green while the VIX is down 3% to trade below 15.
Keep Reading →
October 28 - Market Movers, News
Bringing something new to the table is something that seems to be difficult these days, considering that many things have already been done, have already been invented, and have...
Keep Reading →
October 26 - Hedge Funds, Lists, News
In this article, we will analyze the latest events surrounding Amazon.com, Inc.
Keep Reading →
October 13 - News, Tech
The major indexes opened higher on the last trading day of the quarter as some investors remain on the sidelines due to the Deutsche Bank uncertainty.
Keep Reading →
September 30 - News
OrbiMed Advisors LLC is the world’s largest healthcare-focused investment firm, managing roughly $15 billion in net assets under management.
Keep Reading →
April 1 - Hedge Funds, News
The market has been volatile as the Federal Reserve winds down its easy money policies.
Keep Reading →
December 1 - Hedge Funds, News
Sivik Global Healthcare is a Greenwich, Connecticut-based healthcare-focused hedge fund founded by Krishen Sud in 2006.
Keep Reading →
November 9 - Hedge Fund Analysis, Hedge Funds, News
We have seen a copy of Viking Global's third quarter investor letter.
Keep Reading →
February 5 - Hedge Funds, News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has, once again, shown today why biopharmaceuticals companies are so popular with investors, especially those with a speculative...
Keep Reading →
October 17 - News
Samuel Isaly's Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr.
Keep Reading →
March 6 - Hedge Funds, News
More than anything, biotech companies need investors who are true believers in their products.
Keep Reading →
September 17 - News
French drugmaker Sanofi SA (ADR) (NYSE:SNY) counted that much money in its coffers as of the end of June, including cash, cash equivalents, and short-term investments.
Keep Reading →
September 17 - News
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Keep Reading →
September 16 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 14 - News
The last several months have been remarkably exciting in the biotech space.
Keep Reading →
September 11 - News
Based on today's economic data, you would certainly have expected a more robust rally than what the broad-based S&P 500 (INDEXSP:.INX) ended up gaining, but beggars can't be...
Keep Reading →
September 4 - News
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Keep Reading →
August 29 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
August 27 - News
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
Keep Reading →
August 26 - News
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Keep Reading →
August 26 - News
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Keep Reading →
August 26 - News
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 25 - News
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Keep Reading →
August 23 - News
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Keep Reading →
August 22 - News
At some point, a company reaches a level of maximum valuation. It doesn't mean the company becomes bad, but rather all upside is priced in and future gains are limited.
Keep Reading →
August 22 - News
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Keep Reading →
August 21 - News
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Keep Reading →
August 21 - News
Earlier this year, in May, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was soaring on news of FDA approval of the Eylea injection.
Keep Reading →
August 12 - News
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection.
Keep Reading →
August 12 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) closed Tuesday down over 6% following a second quarter report that missed estimates.
Keep Reading →
August 9 - News
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector.
Keep Reading →
August 8 - News
It is not uncommon for a biotechnology company to be valued solely on the potential of one drug.
Keep Reading →
August 8 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 7 - News
